Barclays PLC Raises Stock Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Barclays PLC lifted its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) by 285.2% during the 3rd quarter, Holdings Channel reports. The firm owned 84,477 shares of the biopharmaceutical company’s stock after buying an additional 62,549 shares during the period. Barclays PLC’s holdings in Regulus Therapeutics were worth $132,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Creative Planning acquired a new stake in Regulus Therapeutics during the 3rd quarter worth approximately $26,000. SG Americas Securities LLC purchased a new stake in shares of Regulus Therapeutics during the third quarter worth $33,000. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics during the third quarter worth $46,000. Rhumbline Advisers purchased a new stake in shares of Regulus Therapeutics during the second quarter worth $136,000. Finally, Tyche Wealth Partners LLC grew its stake in shares of Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 95,694 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Stock Down 1.3 %

RGLS opened at $1.49 on Thursday. The firm has a market cap of $97.60 million, a price-to-earnings ratio of -1.39 and a beta of 1.60. The business’s 50 day moving average is $1.54 and its two-hundred day moving average is $1.61. Regulus Therapeutics Inc. has a 52 week low of $1.08 and a 52 week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Equities analysts expect that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on RGLS shares. StockNews.com upgraded shares of Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.